Precision medication: An illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics

被引：13

作者：

Bain, Kevin T. ^{[1
,2
]}

McGain, David ^{[1
]}

Cicali, Emily J. ^{[3
]}

Knowlton, Calvin H. ^{[1
]}

Michaud, Veronique ^{[1
,4
]}

Turgeon, Jacques ^{[1
,4
]}

机构：

[1] Tabula Rasa HealthCare, 228 Strawbridge Dr, Moorestown, NJ 08057 USA

[2] Univ Sci, Dept Pharm, Philadelphia, PA USA

[3] Univ Florida, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA

[4] Univ Montreal, Fac Pharm, Montreal, PQ, Canada

来源：

CLINICAL CASE REPORTS | 2020年 / 8卷 / 02期

关键词：

drug interactions; pharmacogenomics; phenoconversion; precision medication; precision medicine; DRUG-DRUG INTERACTION; PLATELET-FUNCTION; CYP2C19; GENOTYPE; CLOPIDOGREL; OMEPRAZOLE; PHARMACOKINETICS; PANTOPRAZOLE; POLYMORPHISMS; CROSSOVER; RISK;

D O I：

10.1002/ccr3.2604

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Precision medication entails selecting the precise medication, dose, and timing of administration. Multi-drug interactions and genetics significantly affect precision medication. In this article, we present two simulated cases for real-world applications of precision medication. Clinicians may need to acquire additional skills to apply the principles illustrated by these cases.

引用

页码：305 / 312

页数：8

共 35 条

[1] Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies [J].

Angiolillo, D. J. ;

Gibson, C. M. ;

Cheng, S. ;

Ollier, C. ;

Nicolas, O. ;

Bergougnan, L. ;

Perrin, L. ;

LaCreta, F. P. ;

Hurbin, F. ;

Dubar, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (01) :65-74

[2]

[Anonymous], 2017, PLAV CLOP

[3] Rosuvastatin-warfarin drug interaction [J].

Barry, M .

LANCET, 2004, 363 (9405) :328-328

[4] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite [J].

Boulenc, Xavier ;

Djebli, Nassim ;

Shi, Juan ;

Perrin, Laurent ;

Brian, William ;

Van Horn, Robert ;

Hurbin, Fabrice .

DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) :187-197

[5]

Bristol-Myers Squibb, 2017, COUM WARF SOD

[6] Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study [J].

Cuisset, Thomas ;

Frere, Corinne ;

Quilici, Jacques ;

Poyet, Raphael ;

Gaborit, Benedicte ;

Bali, Laurent ;

Brissy, Olivier ;

Morange, Pierre-Emmanuel ;

Alessi, Marie-Christine ;

Bonnet, Jean-Louis .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (13) :1149-1153

[7] Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care [J].

DeGorter, Marianne K. ;

Tirona, Rommel G. ;

Schwarz, Ute I. ;

Choi, Yun-Hee ;

Dresser, George K. ;

Suskin, Neville ;

Myers, Kathryn ;

Zou, GuangYong ;

Iwuchukwu, Otito ;

Wei, Wei-Qi ;

Wilke, Russell A. ;

Hegele, Robert A. ;

Kim, Richard B. .

CIRCULATION-CARDIOVASCULAR GENETICS, 2013, 6 (04) :400-408

[8] Prevalence and Risk of Potential Cytochrome P450-Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy [J].

Doan, Julie ;

Zakrzewski-Jakubiak, Hubert ;

Roy, Julie ;

Turgeon, Jacques ;

Tannenbaum, Cara .

ANNALS OF PHARMACOTHERAPY, 2013, 47 (03) :324-332

[9] Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel [J].

Fernando, H. ;

Bassler, N. ;

Habersberger, J. ;

Sheffield, L. J. ;

Sharma, R. ;

Dart, A. M. ;

Peter, K. H. ;

Shaw, J. A. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (08) :1582-1589

[10] Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties [J].

Ferri, Nicola ;

Corsini, Alberto ;

Bellosta, Stefano .

DRUGS, 2013, 73 (15) :1681-1709

← 1 2 3 4 →